The University of Michigan Comprehensive Cancer Center (UMCCC) requests renewal of its core grant in support of Senior Leadership, Programs, and Shared Core Facilities. A core grant to support the UMCCC was initially awarded by the NCI in 1988, with continuous funding since then. Dr. Max Wicha, the founding Director of the Cancer Center, continues to serve as Director. The Center provides an organizational framework to promote interdisciplinary cancer research through the development of defined clinical, basic, and prevention programs in cancer research and the development of shared core resources. In 1997 the Center moved into a new $88 million facility which houses the Center's outpatient clinics as well as many of its research laboratories. The Cancer Center has continued to experience considerable growth over this grant period with 70 new faculty recruited and an 85% increase in NCI funding. The Cancer Center's 13 research programs include the basic research programs in Cancer Genetics, Cancer Cell Biology, Molecular Therapeutics, Radiation Sciences, and Molecular Imaging. Clinical research programs include Prostate/Urological, Breast, Leukemia/Lymphoma-BMT, Gl, Childhood Cancers, and Head & Neck cancers. The prevention programs include two programs: Biomedical Prevention and Socio-Behavioral. Support is requested for a total of 16 shared core facilities. These include Clinical Trials, Biostatistics, Tissue Procurement, Tumor Imaging, DNA Sequencing, Morphology, Flow Cytometry, Experimental Irradiation, Animal Facility, Transgenic Mouse, Vector Core, Immune Monitoring, cDNA Affymetrix and Microarray and three new cores including Proteomics, Bioinformatics, and Health Communications. Funds are also requested for development, planning and evaluation, and administration to support Center goals. The Medical Center has made substantial commitments to the Cancer Center of approximately $175 million. Its 285 UMCCC members receive over $82 million in research funding, including over $37 million in annual direct NCI support. The UMCCC has had a major impact on cancer research as evidenced by publishing at least 315 articles in high impact journals, placing 52% of UMCCC intervention accruals onto investigator-initiated trials and consistently ranking among the top ten Cancer Centers nationally for NCI funding over this grant period.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA046592-21S1
Application #
7681337
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1997-06-01
Project End
Budget Start
2008-09-03
Budget End
2009-05-31
Support Year
21
Fiscal Year
2008
Total Cost
$61,058
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Hoban, Connor W; Beesley, Lauren J; Bellile, Emily L et al. (2018) Individualized outcome prognostication for patients with laryngeal cancer. Cancer 124:706-716
Maust, Joel D; Frankowski-McGregor, Christy L; Bankhead 3rd, Armand et al. (2018) Cyclooxygenase-2 Influences Response to Cotargeting of MEK and CDK4/6 in a Subpopulation of Pancreatic Cancers. Mol Cancer Ther 17:2495-2506
Arthur, Anna E; Goss, Amy M; Demark-Wahnefried, Wendy et al. (2018) Higher carbohydrate intake is associated with increased risk of all-cause and disease-specific mortality in head and neck cancer patients: results from a prospective cohort study. Int J Cancer 143:1105-1113
Valenciaga, Anisley; Saji, Motoyasu; Yu, Lianbo et al. (2018) Transcriptional targeting of oncogene addiction in medullary thyroid cancer. JCI Insight 3:
Akkina, Sarah R; Kim, Roderick Y; Stucken, Chaz L et al. (2018) Is There a Difference in Staging and Treatment of Head and Neck Squamous Cell Tumors Between Tertiary Care and Community-Based Institutions? Laryngoscope Investig Otolaryngol 3:290-295
Anwar, Talha; Arellano-Garcia, Caroline; Ropa, James et al. (2018) p38-mediated phosphorylation at T367 induces EZH2 cytoplasmic localization to promote breast cancer metastasis. Nat Commun 9:2801
Giraldez, Maria D; Spengler, Ryan M; Etheridge, Alton et al. (2018) Comprehensive multi-center assessment of small RNA-seq methods for quantitative miRNA profiling. Nat Biotechnol 36:746-757
Hartlerode, Andrea J; Regal, Joshua A; Ferguson, David O (2018) Reversible mislocalization of a disease-associated MRE11 splice variant product. Sci Rep 8:10121
Fritsche, Lars G; Gruber, Stephen B; Wu, Zhenke et al. (2018) Association of Polygenic Risk Scores for Multiple Cancers in a Phenome-wide Study: Results from The Michigan Genomics Initiative. Am J Hum Genet 102:1048-1061
Haley, Henry R; Shen, Nathan; Qyli, Tonela et al. (2018) Enhanced Bone Metastases in Skeletally Immature Mice. Tomography 4:84-93

Showing the most recent 10 out of 1493 publications